Depression and Anxiety in Patients with Multiple Sclerosis: A Retrospective Study on the Impact of Glatiramer Acetate

Year 2021, Volume: 13 Issue: 1, 1 - 10, 30.06.2021

Ali Ulvi Uca , Faruk Ömer Odabaş Mustafa Altaş , Faruk Uguz , Osman Serhat Tokgöz

Abstract

Objective: It has been reported that of disease-modifying therapies used in treatment of relapsing-remitting MS (RRMS) may affect mood of the patients. This study aims to investigate the impact of glatiramer acetate (GA) on depressive and anxiety symptoms in patients with RRMS.
Methods: The study included 31 patients who were admitted to the neurology clinic, and who were diagnosed with RRMS. To assess depressive and anxiety symptoms in the patients before and after the treatment with GA was used the Center Epidemiologic Studies Depression Scale (CES-D) and the Hospital Anxiety and Depression Scale (HAD), respectively.
Results: Before the treatment, based on the scales CES-D and HAD-Depression scores, 18 (58.1%) and 17 (54.8%) patients had depression, respectively and based on HAD-Anxiety 15 (48.4%) patients had anxiety. After the treatment, the same numbers were 8 (25.8%), 9 (29.0%), and 7 (22.6%), respectively. The statistical analyses indicated that the mean scores of CES-D (t=4.51, P=0.000), HAD-Depression (t=2.91, P=0.007), HAD-Anxiety (t=2.78, P=0.009) and HAD-Total (t=3.15, P=0.004) significantly decreased from the onset of treatment to the end of treatment.
Conclusion: Results of the present study suggest that GA may be useful effects on depressive and anxiety symptoms rather than negative effects in RRMS patients.

Keywords

Multiple sclerosis, glatiramer acetate, depression, anxiety

References

• 1-Gauthier SA, Glanz BI, Mandel M, et al. A model for the comprehensive investigation of a chronic autoimmune disease: the multiple sclerosis CLIMB study. Autoimmun Rev. 2006;5: 532–536.
• 2-Ciampi E, Uribe-San-Martin R, Soler B, et al. Prevalence of comorbidities in Multiple Sclerosis and impact on physical disability according to disease phenotype. Mult Scler Relat Disord. 2020;46:102565. Online ahead of print.
• 3-Hauer L, Perneczky J, Sellner J. A global view of comorbidity in multiple sclerosis: a systematic review with a focus on regional differences, methodology, and clinical implications. J Neurol. 2020. Online ahead of print.
• 4-Tezcan AE. Differential diagnosis of depression. Duygudurum Bozuklukları Dizisi 2000; 1:77-98.
• 5-Boz C, Terzi M. [Semptoms of MS]. Hastalar İçin Soru ve Yanıtlarla Multipl Skleroz. 1. Baskı. Trabzon: İber Matbaacılık; 2010. p.18-33.
• 6-Marrie RA, Reingold S, Cohen J, et al. The incidence and prevalence of psychiatric disorders in multiple sclerosis: A systematic review. . Mult Scler. 2015; 21: 305–317.
• 7-Solaro C, Gamberini G, Masuccio FG. Depression in Multiple Sclerosis: Epidemiology, Aetiology, Diagnosis and Treatment. CNS Drugs. 2018;32:117-133.
• 8-Feinstein A. Multiple sclerosis and depression. Multiple Sclerosis. 2011;17: 1276-1281.
• 9-Lana-Peixoto MA, Teixeira AL Jr, Haase VG. Interferon beta 1A induced depression and suicidal ideation in multiple sclerosis. Arq Neuropsiquiatr. 2002;60:721–724.
• 10-Patten SB, Metz LM. Interferon beta-1 a and depression in relapsing-remitting multiple sclerosis: an analysis of depression data from the PRISMS clinical trial. Mult Scler. 2001;7:243-248.
• 11-Arnon R, Aharoni R. Glatiramer Acetate: from Bench to Bed and Back. Isr Med Assoc J. 2019; 21: 151-157.
• 12-Boziki M, Lagoudaki R, Melo P, et al. Induction of apoptosis in CD4(+) T-cells is linked with optimal treatment response in patients with Relapsing-Remitting Multiple Sclerosis treated with Glatiramer Acetate. J Neurol Sci. 2019; 401:43-50.
• 13-Patten SB, Francis G, Metz LM, et al. The relationship between depression and interferon beta-1a therapy in patients with multiple sclerosis. Mult Scler. 2005;1:175–181.
• 14-Ziemssen T, Calabrese P, Penner IK, et al. QualiCOP: real-world effectiveness, tolerability, and quality of life in patients with relapsing-remitting multiple sclerosis treated with glatiramer acetate, treatment-naı¨ve patients, and previously treated patients. J Neurol. 2016; 263: 784-791.
• 15-Radloff LS. The CES-D Scale: A Self-Report Depression Scale for Research in the General Population. Appl Psychol Meas 1977;1:385-401.
• 16-Spijker J, Van Der Wurff FB, Poort EC, et al. Depression in first generation labour migrants in Western Europe: the utility of the Center for Epidemiologic Studies Depression Scale (CES-D). Int J Geriatr Psychiatry 2004; 19: 538-544.
• 17-Aydemir Ö, Güvenir T, Küey L, et al. Hastane anksiyete ve depresyon ölçeği Türkçe formunun geçerlilik ve güvenilirliği. Türk Psikiyatri Dergisi 1977;8: 280-287.
• 18-Fricska-Nagy Z, Füvesi J, Rózsa C, et al . The effects of fatigue, depression and the level of disability on the health-related quality of life of glatiramer acetate-treated relapsing-remitting patients with multiple sclerosis in Hungary. Mult Scler Relat Disord. 2016 ;7:26-32.
• 19-Kirzinger SS, Jones J, Siegwald A, et al. Relationship Between Disease-Modifying Therapy and Depression in Multiple Sclerosis. Int J MS Care. 2013; 15: 107–112.
• 20-Schippling S, O'Connor P, Knappertz V, et al. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol 2016; 263: 1418–1426.
• 21-Shih-Jen Tsai. Glatiramer acetate could be a potential antidepressant through its neuroprotective and anti-inflammatory effects. Medical Hypotheses 2007; 69: 145–148.